Eyepoint Pharmaceuticals Inc (EYPT) — Capital Reinvestment Ratio
Latest as of June 2023:
0.01x
Eyepoint Pharmaceuticals Inc (EYPT) has a Capital Reinvestment Ratio of 0.01x as of June 2023, meaning it reinvests 0% of its operating cash flow ($57.02 Million) in capital expenditures ($396.00K). See Eyepoint Pharmaceuticals Inc (EYPT) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.01x
Capex / Operating Cash Flow
Operating Cash Flow
$57.02 Million
USD
Capital Expenditures
$396.00K
USD
Data as of
Jun 2023
Most recent filing
Eyepoint Pharmaceuticals Inc Capital Reinvestment Ratio (2010–2023)
This chart tracks Eyepoint Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc (2010–2023)
Year-by-year Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc from 2010 to 2023. For live market cap and broader valuation context, see market value of Eyepoint Pharmaceuticals Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.86x | $1.88 Million | $3.48 Million | ▲ +11780.6% |
| 2015 | 0.02x | $10.30 Million | $161.00K | ▲ +931.8% |
| 2010 | 0.00x | $9.90 Million | $15.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow